Things I am noting.
2 Bilion shares issued all of which are below issue price, plenty of tax loss selling. Thats is a lot of stock that could be off set against gains.
Some of the last policy holdouts are in their review cycle & may add additional momentum to sales in the coming quarters.
Of the below there will be male & female surgeons, only thing that matters is they indicated after initial contact that they were still interested in SOZO & my words "generating revenue while giving patents a better outcome"
I don't know what IPD definition of significant means, I guess at much larger than or more notable than pervious amounts. I know that PB said sale time around 6 months and that fits with an increase in sales for 2025 4C from the data below.
The key for me now is how well the sales teams can turn these leads into revenue, I estimate over 1000 leads now.
There are more Oppurtunites with SOZO than just BCRL.
Accumulate.
Acclivity
Add to My Watchlist
What is My Watchlist?
